WO2002024158A8 - Pulmonary delivery in treating disorders of the central nervous system - Google Patents
Pulmonary delivery in treating disorders of the central nervous systemInfo
- Publication number
- WO2002024158A8 WO2002024158A8 PCT/US2001/029311 US0129311W WO0224158A8 WO 2002024158 A8 WO2002024158 A8 WO 2002024158A8 US 0129311 W US0129311 W US 0129311W WO 0224158 A8 WO0224158 A8 WO 0224158A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- central nervous
- nervous system
- drug
- particles
- pulmonary delivery
- Prior art date
Links
- 210000003169 central nervous system Anatomy 0.000 title abstract 2
- 230000002685 pulmonary effect Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 4
- 229940079593 drug Drugs 0.000 abstract 3
- 239000002245 particle Substances 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK01971210.8T DK1318785T3 (en) | 2000-09-19 | 2001-09-19 | PULMONAL ADMINISTRATION OF L-DOPA |
AU9112201A AU9112201A (en) | 2000-09-19 | 2001-09-19 | Pulmonary delivery in treating disorders of the central nervous system |
AU2001291122A AU2001291122B2 (en) | 2000-09-19 | 2001-09-19 | Pulmonary delivery in treating disorders of the central nervous system |
ES01971210.8T ES2621549T3 (en) | 2000-09-19 | 2001-09-19 | L-Dopa pulmonary administration |
EP01971210.8A EP1318785B1 (en) | 2000-09-19 | 2001-09-19 | Pulmonary delivery of l-dopa |
JP2002528195A JP5421510B2 (en) | 2000-09-19 | 2001-09-19 | Pulmonary delivery in the treatment of disorders of the central nervous system |
CA2421974A CA2421974C (en) | 2000-09-19 | 2001-09-19 | Pulmonary delivery in treating disorders of the central nervous system |
CY20171100358T CY1118851T1 (en) | 2000-09-19 | 2017-03-21 | Pulmonary administration of L-DOPA |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/665,252 US6514482B1 (en) | 2000-09-19 | 2000-09-19 | Pulmonary delivery in treating disorders of the central nervous system |
US09/665,252 | 2000-09-19 | ||
US09/877,734 | 2001-06-08 | ||
US09/877,734 US6613308B2 (en) | 2000-09-19 | 2001-06-08 | Pulmonary delivery in treating disorders of the central nervous system |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2002024158A2 WO2002024158A2 (en) | 2002-03-28 |
WO2002024158A3 WO2002024158A3 (en) | 2002-09-19 |
WO2002024158A8 true WO2002024158A8 (en) | 2003-02-20 |
Family
ID=27099159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/029311 WO2002024158A2 (en) | 2000-09-19 | 2001-09-19 | Pulmonary delivery in treating disorders of the central nervous system |
Country Status (10)
Country | Link |
---|---|
US (7) | US6613308B2 (en) |
EP (2) | EP3061453A1 (en) |
JP (2) | JP5421510B2 (en) |
AU (2) | AU9112201A (en) |
CA (1) | CA2421974C (en) |
CY (1) | CY1118851T1 (en) |
DK (1) | DK1318785T3 (en) |
ES (1) | ES2621549T3 (en) |
PT (1) | PT1318785T (en) |
WO (1) | WO2002024158A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8955512B2 (en) | 2001-06-05 | 2015-02-17 | Alexza Pharmaceuticals, Inc. | Method of forming an aerosol for inhalation delivery |
US8991387B2 (en) | 2003-05-21 | 2015-03-31 | Alexza Pharmaceuticals, Inc. | Self-contained heating unit and drug-supply unit employing same |
US9211382B2 (en) | 2001-05-24 | 2015-12-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
Families Citing this family (157)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020052310A1 (en) * | 1997-09-15 | 2002-05-02 | Massachusetts Institute Of Technology The Penn State Research Foundation | Particles for inhalation having sustained release properties |
US7779020B2 (en) * | 2002-03-01 | 2010-08-17 | International Business Machines Corporation | Small-footprint applicative query interpreter method, system and program product |
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
CA2307278A1 (en) * | 2000-04-28 | 2001-10-28 | University Of British Columbia | Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine |
FR2812545B1 (en) * | 2000-08-03 | 2003-03-28 | Air Liquide Sante Int | INHALABLE DRUG AEROSOL FOR TREATMENT OR PREVENTION OF SWEETNESS |
US6613308B2 (en) * | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
JP2005503425A (en) | 2001-05-24 | 2005-02-03 | アレックザ モレキュラー デリヴァリー コーポレイション | Delivery of drug ester by the prescribed inhalation route |
US20080038363A1 (en) * | 2001-05-24 | 2008-02-14 | Zaffaroni Alejandro C | Aerosol delivery system and uses thereof |
DE60227660D1 (en) * | 2001-05-24 | 2008-08-28 | Alexza Pharmaceuticals Inc | RELEASE OF ANTIEMETICS ON THE INHALATION PATH |
WO2002094230A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of sedative-hypnotics trough an inhalation route |
WO2002094241A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of compounds for the treatment of migraine through an inhalation route |
EP1392258B1 (en) * | 2001-05-24 | 2008-11-26 | Alexza Pharmaceuticals, Inc. | Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route |
US6759029B2 (en) * | 2001-05-24 | 2004-07-06 | Alexza Molecular Delivery Corporation | Delivery of rizatriptan and zolmitriptan through an inhalation route |
WO2002094238A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of anti-migraine compounds through an inhalation route |
US6805853B2 (en) | 2001-11-09 | 2004-10-19 | Alexza Molecular Delivery Corporation | Delivery of diazepam through an inhalation route |
WO2002094237A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of beta-blockers through an inhalation route |
US7645442B2 (en) | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
DE60230609D1 (en) * | 2001-05-24 | 2009-02-12 | Alexza Pharmaceuticals Inc | ADMINISTRATION OF NON-TEROIDAL INFLAMMATION OF INHALATION OF ACTIVE SUBSTANCES |
WO2002094232A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of antidepressants through an inhalation route |
US20030032638A1 (en) * | 2001-05-24 | 2003-02-13 | Kim John J. | Delivery of benzodiazepines through an inhalation route |
DE60231611D1 (en) * | 2001-05-24 | 2009-04-30 | Alexza Pharmaceuticals Inc | ADMINISTRATION OF OPIOIDES BY INHALATION |
DE10137633A1 (en) * | 2001-08-03 | 2003-02-20 | Boehringer Ingelheim Pharma | Treatment or prophylaxis of attention deficit hyperactivity disorder, using the dopamine agonist pramexipol or its salt |
AU2002363947A1 (en) | 2001-11-21 | 2003-07-24 | Alexza Molecular Delivery Corporation | Delivery of caffeine through an inhalation route |
JP2005514393A (en) | 2001-12-19 | 2005-05-19 | ネクター セラピューティクス | Supplying aminoglycosides to the lung |
JP2005521695A (en) * | 2002-03-20 | 2005-07-21 | アドバンスト インハレーション リサーチ,インコーポレイテッド | Method of administering growth hormone by pulmonary delivery |
ES2300568T3 (en) | 2002-03-20 | 2008-06-16 | Mannkind Corporation | INHALATION APPARATUS |
WO2003079992A2 (en) * | 2002-03-20 | 2003-10-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery for levodopa |
WO2003090681A2 (en) * | 2002-04-24 | 2003-11-06 | Research Development Foundation | SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-κB INHIBITORS AND ANTI-NEOPLASTIC AGENTS |
WO2003094900A1 (en) | 2002-05-13 | 2003-11-20 | Alexza Molecular Delivery Corporation | Delivery of drug amines through an inhalation route |
US20060193788A1 (en) * | 2002-11-26 | 2006-08-31 | Hale Ron L | Acute treatment of headache with phenothiazine antipsychotics |
WO2004000229A2 (en) * | 2002-06-24 | 2003-12-31 | Research Development Foundation | Treatment of human multiple myeloma by curcumin |
SI1531794T1 (en) * | 2002-06-28 | 2017-12-29 | Civitas Therapeteutics, Inc. | Inhalable epinephrine |
US20060094785A1 (en) * | 2002-07-12 | 2006-05-04 | Guttuso Jr Thomas J | Use of amino acids for treatment of various conditions |
JP2006514633A (en) * | 2002-11-26 | 2006-05-11 | アレックザ ファーマシューティカルズ, インコーポレイテッド | Treatment of headache with antipsychotics delivered by inhalation |
US7550133B2 (en) * | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
AU2003294470B2 (en) * | 2002-11-26 | 2009-09-17 | Alexza Pharmaceuticals, Inc. | Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain |
US20040105818A1 (en) | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
US7913688B2 (en) | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
WO2004071491A1 (en) * | 2003-02-04 | 2004-08-26 | Chrysalis Technologies Incorporated | Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem |
JP2006522634A (en) | 2003-04-14 | 2006-10-05 | ベクトゥラ・リミテッド | Device and pharmaceutical composition for improving administration efficiency |
ES2872350T3 (en) * | 2003-06-13 | 2021-11-02 | Civitas Therapeutics Inc | Low Dose Pharmaceutical Powders For Inhalation |
US7462646B2 (en) | 2003-08-26 | 2008-12-09 | Research Development Foundation | Osteoclastogenesis inhibitors and uses thereof |
WO2005020958A2 (en) * | 2003-08-26 | 2005-03-10 | Research Development Foundation | Aerosol delivery of curcumin |
US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
PL1765288T3 (en) | 2004-06-18 | 2013-04-30 | Novartis Ag | Tobramycin formualtions for treatment of endobronchial infections |
MX2007001903A (en) | 2004-08-20 | 2007-08-02 | Mannkind Corp | Catalysis of diketopiperazine synthesis. |
KR101306384B1 (en) | 2004-08-23 | 2013-09-09 | 맨카인드 코포레이션 | Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery |
AU2005290238A1 (en) | 2004-09-18 | 2006-04-06 | Department Of Veterans Affairs | Therapeutic agents trageting the NCCa-ATP channel and methods of use thereof |
AU2005287090A1 (en) | 2004-09-18 | 2006-03-30 | Department Of Veterans Affairs | Therapeutic agents targeting the NCca-ATP channel and methods of use thereof |
GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
US20060134009A1 (en) * | 2004-12-16 | 2006-06-22 | Daniel Deaver | Low dose corticosteroid powders for inhalation |
PT1883665T (en) | 2005-04-22 | 2017-11-14 | Univ Geneve | Polylactide compositions and uses thereof |
JP5465878B2 (en) | 2005-09-14 | 2014-04-09 | マンカインド コーポレイション | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
CN104383546B (en) | 2006-02-22 | 2021-03-02 | 曼金德公司 | Method for improving the pharmaceutical properties of microparticles comprising diketopiperazines and an active agent |
WO2008089103A2 (en) | 2007-01-12 | 2008-07-24 | University Of Maryland, Baltimore | Targeting ncca-atp channel for organ protection following ischemic episode |
US20080275030A1 (en) | 2007-01-19 | 2008-11-06 | Sveinbjorn Gizurarson | Methods and Compositions for the Delivery of a Therapeutic Agent |
AU2008214095B2 (en) | 2007-02-02 | 2014-07-10 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
WO2008098160A1 (en) | 2007-02-09 | 2008-08-14 | University Of Maryland, Baltimore | Antagonists of a non-selective cation channel in neural cells |
KR20090129998A (en) | 2007-02-11 | 2009-12-17 | 맵 파마슈티컬스, 인코포레이티드 | Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile |
EP2121088B1 (en) | 2007-03-09 | 2016-07-13 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
CA3065983C (en) | 2007-06-22 | 2022-07-26 | The United States Of America As Represented By The Department Of Veterans Affairs | Inhibitors of ncca-atp channels for therapy |
WO2009011782A2 (en) * | 2007-07-13 | 2009-01-22 | Abbott Biotechnology Ltd. | METHODS AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa INHIBITOR |
GB0721394D0 (en) * | 2007-10-31 | 2007-12-12 | Vectura Group Plc | Compositions for trating parkinson's disease |
GB2454480A (en) * | 2007-11-07 | 2009-05-13 | Vectura Group Plc | Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders |
US20090247537A1 (en) * | 2008-03-25 | 2009-10-01 | William Dale Overfield | Methods for preventing or treating bruxism using dopaminergic agents |
CN104689432B (en) | 2008-06-13 | 2018-07-06 | 曼金德公司 | Diskus and the system for drug conveying |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
JP5479465B2 (en) | 2008-06-20 | 2014-04-23 | マンカインド コーポレイション | Interactive device and method for profiling inhalation efforts in real time |
TWI494123B (en) | 2008-08-11 | 2015-08-01 | Mannkind Corp | Use of ultrarapid acting insulin |
CA2732892C (en) * | 2008-08-15 | 2020-12-15 | Forest Laboratories Holdings Limited | Stable solid formulation of a gc-c receptor agonist polypeptide suitable for oral administration |
JP2012502915A (en) | 2008-09-15 | 2012-02-02 | バイオビスタ インコーポレイテッド | Compositions and methods for treating epilepsy |
EP2326318A4 (en) | 2008-09-16 | 2012-05-23 | Univ Maryland | Sur1 inhibitors for therapy |
US8765817B1 (en) | 2008-12-03 | 2014-07-01 | Arrowhead Center, Inc. | Selective inhibitors of EG5 motors and methods of use |
US8349899B1 (en) | 2008-12-03 | 2013-01-08 | Arrowhead Center, Inc. | Selective inhibitors of EG5 motors and methods of use |
US8555875B2 (en) | 2008-12-23 | 2013-10-15 | Map Pharmaceuticals, Inc. | Inhalation devices and related methods for administration of sedative hypnotic compounds |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
PL2405963T3 (en) | 2009-03-11 | 2014-04-30 | Mannkind Corp | Apparatus, system and method for measuring resistance of an inhaler |
EP2228054A1 (en) * | 2009-03-13 | 2010-09-15 | ITALFARMACO S.p.A. | Riluzole aqueous suspensions |
JP5671001B2 (en) | 2009-03-26 | 2015-02-18 | パルマトリックス,インコーポレイテッド | Dry powder formulation and method for treating lung disease |
US20120294868A1 (en) | 2009-04-24 | 2012-11-22 | Edwards James R | Anti-tgf-beta induction of bone cell function and bone growth |
EP2440184B1 (en) | 2009-06-12 | 2023-04-05 | MannKind Corporation | Diketopiperazine microparticles with defined specific surface areas |
DK2456304T3 (en) | 2009-07-24 | 2015-08-31 | Baylor College Medicine | METHODS OF MODULATING acids with branched chains and uses thereof |
US8748573B2 (en) * | 2009-08-06 | 2014-06-10 | Ironwood Pharmaceuticals, Inc. | Formulations comprising linaclotide |
WO2011056889A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
AU2011218009B2 (en) | 2010-02-17 | 2016-11-03 | Ironwood Pharmaceuticals, Inc | Treatments for gastrointestinal disorders |
RU2571331C1 (en) | 2010-06-21 | 2015-12-20 | Маннкайнд Корпорейшн | Systems and methods for dry powder drug delivery |
PL2603232T3 (en) | 2010-08-11 | 2020-05-18 | Ironwood Pharmaceuticals, Inc. | Stable formulations of linaclotide |
WO2012024535A2 (en) | 2010-08-18 | 2012-02-23 | Fred Hutchinson Cancer Research Center | Methods for determining the presence or risk of developing facioscapulohumeral dystrophy (fshd) |
EP2448571B1 (en) | 2010-08-30 | 2013-06-12 | Pulmatrix, Inc. | Respirably dry powder comprising calcium lactate, sodium chloride and leucine |
MX354828B (en) | 2010-09-29 | 2018-03-22 | Pulmatrix Operating Co Inc | Monovalent metal cation dry powders for inhalation. |
DK2694402T3 (en) | 2011-04-01 | 2017-07-03 | Mannkind Corp | BLISTER PACKAGE FOR PHARMACEUTICAL CYLINDER AMPULS |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
AU2012287120B2 (en) | 2011-07-22 | 2017-02-23 | The University Of Chicago | Treatments for migraine and related disorders |
EP2776055B1 (en) | 2011-08-17 | 2016-12-14 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
WO2013057592A2 (en) | 2011-09-14 | 2013-04-25 | King Abdullah University Of Science And Technology | Treatment of sickle cell disease |
WO2013041969A2 (en) | 2011-09-21 | 2013-03-28 | King Abdullah University Of Science And Technology | Didemnin biosynthetic gene cluster in tistrella mobilis |
WO2013043985A1 (en) | 2011-09-23 | 2013-03-28 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
AU2012328885B2 (en) | 2011-10-24 | 2017-08-31 | Mannkind Corporation | Methods and compositions for treating pain |
IL298436B1 (en) | 2012-01-23 | 2024-03-01 | Sage Therapeutics Inc | Pharmaceutical compositions comprising allopregnanolone |
AU2013221448B2 (en) | 2012-02-16 | 2017-02-23 | The University Of Toledo | Xenoantigen-displaying anti-cancer vaccines and method of making |
US20150018362A1 (en) | 2012-02-27 | 2015-01-15 | Biovista, Inc. | Compositions and methods for treating mitochondrial diseases |
CN107596518B (en) | 2012-02-29 | 2021-04-23 | 普马特里克斯营业公司 | Inhalable dry powder |
AR092821A1 (en) | 2012-04-20 | 2015-05-06 | Sucampo Ag | CONJUGATE OF GRASO-POLYMER ACID DERIVATIVE |
CN104582691A (en) | 2012-05-23 | 2015-04-29 | 俄亥俄州立大学 | Lipid-coated albumin nanoparticle compositions and methods of making and method of using the same |
AU2013289957B2 (en) | 2012-07-12 | 2017-02-23 | Mannkind Corporation | Dry powder drug delivery systems and methods |
US20140050789A1 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
WO2014066206A1 (en) * | 2012-10-22 | 2014-05-01 | Civitas Therapeutics , Inc. | Reducing inter-patient variability of levodopa plasma concentrations |
WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
US8545878B1 (en) * | 2012-11-09 | 2013-10-01 | Civitas Therapeutics, Inc. | Capsules containing high doses of levodopa for pulmonary use |
WO2014074797A1 (en) * | 2012-11-09 | 2014-05-15 | Civitas Therapeutics, Inc. | Ultra low density pulmonary powders |
US20150313915A1 (en) | 2012-11-30 | 2015-11-05 | The Regents Of The University Of California | Anticonvulsant activity of steroids |
US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
FR3000392B1 (en) * | 2012-12-27 | 2015-03-27 | Virbac | NOVEL VETERINARY PHARMACEUTICAL COMPOSITIONS AND PROCESS FOR THEIR PREPARATION |
WO2014160339A1 (en) | 2013-03-13 | 2014-10-02 | Board Of Regents, The University Of Texas System | Compounds for treating inflammatory and hyperproliferative diseases |
EP3587404B1 (en) | 2013-03-15 | 2022-07-13 | MannKind Corporation | Microcrystalline diketopiperazine compositions, methods for preparation and use thereof |
US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
EP2978482B1 (en) * | 2013-03-26 | 2022-05-18 | Optinose AS | Nasal administration |
WO2014165303A1 (en) | 2013-04-01 | 2014-10-09 | Pulmatrix, Inc. | Tiotropium dry powders |
CN105473133A (en) * | 2013-04-30 | 2016-04-06 | 欧缇托匹克公司 | Dry powder formulations and methods of use |
BR112016000937A8 (en) | 2013-07-18 | 2021-06-22 | Mannkind Corp | dry powder pharmaceutical formulations, method for making a dry powder formulation and use of a dry powder pharmaceutical formulation |
JP2016530930A (en) | 2013-08-05 | 2016-10-06 | マンカインド コーポレイション | Ventilation device and method |
JP6667437B2 (en) | 2013-12-02 | 2020-03-18 | ベイラー カレッジ オブ メディスンBaylor College Of Medicine | Identification of novel polypeptide hormones for maintaining optimal weight and blood glucose |
CA2977083A1 (en) | 2014-02-20 | 2015-08-27 | Kambiz Yadidi | Dry powder formulations for inhalation |
WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
US9693994B2 (en) | 2014-04-09 | 2017-07-04 | Research Development Foundation | Class IIa HDAC inhibitors for the treatment of infection |
US20170296498A1 (en) * | 2014-04-21 | 2017-10-19 | Civitas Therapeutics, Inc. | Rapid Relief of Motor Fluctuations in Parkinson's Disease |
WO2016025202A1 (en) | 2014-08-14 | 2016-02-18 | The Regents Of The University Of Colorado | Antibody-sirna conjugates and uses therefor |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
MX2017005692A (en) | 2014-10-31 | 2017-08-07 | Glaxosmithkline Ip Dev Ltd | Powder formulation. |
WO2016073184A1 (en) | 2014-11-04 | 2016-05-12 | Dana Farber Cancer Institute, Inc. | Compositions and methods for treating multiple myeloma |
WO2016172026A1 (en) | 2015-04-20 | 2016-10-27 | The Board Of Regents Of The University Of Texas System | Clec11a is a bone growth agent |
AU2016257729A1 (en) * | 2015-05-01 | 2017-11-09 | Civitas Therapeutics, Inc. | Zolmitriptan powders for pulmonary delivery |
WO2016205615A1 (en) | 2015-06-17 | 2016-12-22 | The Johns Hopkins University | Tdp-43 in degenerative disease |
JP2018524346A (en) | 2015-07-02 | 2018-08-30 | サイヴィタス セラピューティックス,インコーポレイテッド | Triptan powder for pulmonary delivery |
WO2017132321A1 (en) | 2016-01-29 | 2017-08-03 | The Johns Hopkins University | Novel inhibitors of bacterial growth |
US11040025B2 (en) | 2016-02-17 | 2021-06-22 | The Johns Hopkins University | Oxazolidinone for treatment of infections with Mycobacterium tuberculosis |
WO2017147370A1 (en) | 2016-02-24 | 2017-08-31 | The Johns Hopkins University | Novel antiviral proteins and their uses in therapeutic methods |
US10888549B2 (en) | 2016-03-07 | 2021-01-12 | The Johns Hopkins University | Pharmaceutical agents targeting cancer stem cells |
MA43815A (en) | 2016-03-08 | 2021-04-07 | Sage Therapeutics Inc | NEUROACTIVE STEROIDS, COMPOSITIONS, AND THEIR USES |
CN109790545A (en) | 2016-03-10 | 2019-05-21 | 约翰·霍普金斯大学 | Generate the method and therapeutical uses of the monomer diphtheria toxin fusion protein without aggregation |
US11203626B2 (en) | 2016-03-10 | 2021-12-21 | The Johns Hopkins University | Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses |
KR20190016938A (en) | 2016-03-17 | 2019-02-19 | 더 존스 홉킨스 유니버시티 | A method for preventing or treating Parkinson's disease by PARANISYLING PARIS |
WO2017173055A1 (en) | 2016-03-30 | 2017-10-05 | The Johns Hopkins University | Olfr90 specificity and methods of detection |
WO2017189483A1 (en) | 2016-04-25 | 2017-11-02 | The Johns Hopkins University | Znt8 assays for drug development and pharmaceutical compositions |
US10568894B2 (en) | 2016-06-03 | 2020-02-25 | Otitopic Inc. | Dry powder formulations for inhalation |
US11149275B2 (en) | 2016-10-10 | 2021-10-19 | The Johns Hopkins University | Device and method to treat esophageal disorders |
WO2018107045A1 (en) * | 2016-12-09 | 2018-06-14 | Alexza Pharmaceuticals, Inc. | Method of treating epilepsy |
US10434089B2 (en) | 2017-01-25 | 2019-10-08 | The Johns Hopkins University | Avibactam and carbapenems antibacterial agents |
US11892457B2 (en) | 2017-07-12 | 2024-02-06 | The Johns Hopkins University | Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis |
US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
KR20230040375A (en) | 2017-09-22 | 2023-03-22 | 오티토픽 인코퍼레이티드 | Dry powder compositions with magnesium stearate |
WO2019099613A1 (en) | 2017-11-16 | 2019-05-23 | University Of Maine System Board Of Trustees | Compositions and methods for modulating endothelial cell migration and angiogenesis |
WO2019118527A1 (en) | 2017-12-14 | 2019-06-20 | The Johns Hopkins University | Novel anti-fungal inhibitors |
EP3921029A4 (en) | 2019-02-07 | 2022-12-07 | Baylor College of Medicine | Periosteal skeletal stem cells in bone repair |
US11717506B2 (en) | 2019-05-07 | 2023-08-08 | The Johns Hopkins University | Neuroprotective compounds for amyotrophic lateral sclerosis |
US11793808B2 (en) | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
JPS6122019A (en) | 1984-07-06 | 1986-01-30 | Tomio Konno | Inhalation cell active chemical and method for using same |
GB8501015D0 (en) | 1985-01-16 | 1985-02-20 | Riker Laboratories Inc | Drug |
JPS63500175A (en) | 1985-05-22 | 1988-01-21 | リポソ−ム テクノロジ−,インコ−ポレイテツド | Liposome inhalation method and inhalation system |
JP2573275B2 (en) * | 1986-03-10 | 1997-01-22 | ブルグハルト,クルト | Pharmaceutical preparations and methods for their production |
IT1228459B (en) | 1989-02-23 | 1991-06-19 | Phidea S R L | INHALER WITH REGULAR AND COMPLETE EMPTYING OF THE CAPSULE. |
US6048857A (en) | 1989-10-17 | 2000-04-11 | Ellinwood, Jr.; Everett H. | Dosing method of administering medicaments via inhalation administration |
US5118494A (en) | 1990-03-23 | 1992-06-02 | Minnesota Mining And Manufacturing Company | Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
JPH05507090A (en) | 1990-05-08 | 1993-10-14 | リポサーム テクノロジー インコーポレイテッド | Direct spray-dried drug/lipid powder compositions |
US5166202A (en) | 1990-09-19 | 1992-11-24 | Trustees Of The University Of Pennsylvania | Method for the treatment of panic disorder |
GB9101592D0 (en) | 1991-01-24 | 1991-03-06 | Glaxo Group Ltd | Compositions |
ATE179605T1 (en) * | 1991-02-09 | 1999-05-15 | B S D Bio Science Dev Snc Di O | ANTIREACTIVE ANTIASTHMATIC EFFECT OF ACETYL SALICYLIC ACID BY INHALATION |
ATE204262T1 (en) | 1991-09-18 | 2001-09-15 | Glaxo Group Ltd | BENZANILIDE DERIVATIVES AS 5-HT1D ANTAGONISTS |
US5457100A (en) | 1991-12-02 | 1995-10-10 | Daniel; David G. | Method for treatment of recurrent paroxysmal neuropsychiatric |
US5756071A (en) | 1992-06-03 | 1998-05-26 | Arrowdean Limited | Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier |
US5284133A (en) | 1992-07-23 | 1994-02-08 | Armstrong Pharmaceuticals, Inc. | Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means |
WO1994008599A1 (en) | 1992-10-14 | 1994-04-28 | The Regents Of The University Of Colorado | Ion-pairing of drugs for improved efficacy and delivery |
US5354885A (en) * | 1992-12-24 | 1994-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Process for preparing ethyl ester of L-DOPA |
MX9603936A (en) | 1994-03-07 | 1997-05-31 | Inhale Therapeutic Syst | Methods and compositions for pulmonary delivery of insulin. |
AU696387B2 (en) * | 1994-05-18 | 1998-09-10 | Inhale Therapeutic Systems, Inc. | Methods and compositions for the dry powder formulation of interferons |
CA2152684A1 (en) | 1994-07-01 | 1996-01-02 | Richard Anthony Henry | Aerosol delivery of midazolam |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US6165463A (en) | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
GB9606188D0 (en) * | 1996-03-23 | 1996-05-29 | Danbiosyst Uk | Pollysaccharide microspheres for the pulmonary delivery of drugs |
US5875776A (en) | 1996-04-09 | 1999-03-02 | Vivorx Pharmaceuticals, Inc. | Dry powder inhaler |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US6503480B1 (en) * | 1997-05-23 | 2003-01-07 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US6103270A (en) | 1996-06-07 | 2000-08-15 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
US6517860B1 (en) * | 1996-12-31 | 2003-02-11 | Quadrant Holdings Cambridge, Ltd. | Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery |
PT954282E (en) | 1997-01-16 | 2005-06-30 | Massachusetts Inst Technology | PREPARATION OF PARTICLES FOR INHALATION |
US5958902A (en) | 1997-04-16 | 1999-09-28 | Wisconsin Alumni Research Foundation | Method and composition for treating sleep apnea |
US6284282B1 (en) * | 1998-04-29 | 2001-09-04 | Genentech, Inc. | Method of spray freeze drying proteins for pharmaceutical administration |
US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
ATE312601T1 (en) | 1999-05-27 | 2005-12-15 | Acusphere Inc | POROUS MEDICINAL MATRICES AND THEIR PRODUCTION PROCESS |
US6858199B1 (en) * | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
US6586008B1 (en) * | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
US6613308B2 (en) * | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
US7090830B2 (en) * | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
WO2002094243A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route |
-
2001
- 2001-06-08 US US09/877,734 patent/US6613308B2/en not_active Expired - Lifetime
- 2001-09-19 ES ES01971210.8T patent/ES2621549T3/en not_active Expired - Lifetime
- 2001-09-19 EP EP15201016.1A patent/EP3061453A1/en not_active Ceased
- 2001-09-19 AU AU9112201A patent/AU9112201A/en active Pending
- 2001-09-19 WO PCT/US2001/029311 patent/WO2002024158A2/en active IP Right Grant
- 2001-09-19 PT PT1971210T patent/PT1318785T/en unknown
- 2001-09-19 EP EP01971210.8A patent/EP1318785B1/en not_active Expired - Lifetime
- 2001-09-19 DK DK01971210.8T patent/DK1318785T3/en active
- 2001-09-19 CA CA2421974A patent/CA2421974C/en not_active Expired - Lifetime
- 2001-09-19 AU AU2001291122A patent/AU2001291122B2/en not_active Expired
- 2001-09-19 JP JP2002528195A patent/JP5421510B2/en not_active Expired - Lifetime
-
2003
- 2003-05-20 US US10/441,968 patent/US6979437B2/en not_active Expired - Lifetime
-
2004
- 2004-01-21 US US10/762,200 patent/US20040228923A1/en not_active Abandoned
- 2004-07-21 US US10/895,577 patent/US20040265242A1/en not_active Abandoned
-
2008
- 2008-07-02 US US12/166,704 patent/US20090162441A1/en not_active Abandoned
-
2011
- 2011-09-13 US US13/231,405 patent/US20120087952A1/en not_active Abandoned
-
2012
- 2012-06-27 JP JP2012144071A patent/JP2012180378A/en not_active Withdrawn
-
2014
- 2014-01-10 US US14/152,492 patent/US20140193501A1/en not_active Abandoned
-
2017
- 2017-03-21 CY CY20171100358T patent/CY1118851T1/en unknown
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9211382B2 (en) | 2001-05-24 | 2015-12-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US9440034B2 (en) | 2001-05-24 | 2016-09-13 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US8955512B2 (en) | 2001-06-05 | 2015-02-17 | Alexza Pharmaceuticals, Inc. | Method of forming an aerosol for inhalation delivery |
US9308208B2 (en) | 2001-06-05 | 2016-04-12 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
US9439907B2 (en) | 2001-06-05 | 2016-09-13 | Alexza Pharmaceutical, Inc. | Method of forming an aerosol for inhalation delivery |
US8991387B2 (en) | 2003-05-21 | 2015-03-31 | Alexza Pharmaceuticals, Inc. | Self-contained heating unit and drug-supply unit employing same |
US9370629B2 (en) | 2003-05-21 | 2016-06-21 | Alexza Pharmaceuticals, Inc. | Self-contained heating unit and drug-supply unit employing same |
Also Published As
Publication number | Publication date |
---|---|
US20040228923A1 (en) | 2004-11-18 |
AU2001291122B2 (en) | 2005-03-10 |
WO2002024158A3 (en) | 2002-09-19 |
CA2421974C (en) | 2011-03-29 |
US20040265242A1 (en) | 2004-12-30 |
AU9112201A (en) | 2002-04-02 |
JP2012180378A (en) | 2012-09-20 |
JP5421510B2 (en) | 2014-02-19 |
DK1318785T3 (en) | 2017-04-03 |
EP1318785B1 (en) | 2016-12-21 |
US20120087952A1 (en) | 2012-04-12 |
US20030235537A1 (en) | 2003-12-25 |
CY1118851T1 (en) | 2018-01-10 |
ES2621549T3 (en) | 2017-07-04 |
EP1318785A2 (en) | 2003-06-18 |
EP3061453A1 (en) | 2016-08-31 |
US6613308B2 (en) | 2003-09-02 |
US20090162441A1 (en) | 2009-06-25 |
WO2002024158A2 (en) | 2002-03-28 |
JP2004509141A (en) | 2004-03-25 |
US20020058009A1 (en) | 2002-05-16 |
CA2421974A1 (en) | 2002-03-28 |
US20140193501A1 (en) | 2014-07-10 |
US6979437B2 (en) | 2005-12-27 |
PT1318785T (en) | 2017-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002024158A8 (en) | Pulmonary delivery in treating disorders of the central nervous system | |
HUP0102892A2 (en) | Drug delivery system comprising a tightly compacted solid medicament stock, process for its preparation and for its use | |
JP2020023542A (en) | Mast cell stabilizers for lung disease treatment | |
WO2003080022A3 (en) | Analgesics for nasal administration | |
WO2017011729A1 (en) | Combination therapies for the treatment of lung diseases | |
AU3400501A (en) | Improvements in or relating to the delivery of oral drugs | |
EA003405B1 (en) | Method and device for delivering an aerosolized active agent to the lungs of a human patient | |
CA2304975A1 (en) | Stabilized preparations for use in metered dose inhalers | |
WO2001074247A3 (en) | Method for measuring changes in the airways of humans and other mammals | |
KR930701992A (en) | How to get rid of mucus secretions that remain in the lungs of patients | |
US7431916B2 (en) | Administration of medicinal dry powders | |
US5679714A (en) | Administration of ketamine for detoxification and treatment of tobacco addiction | |
JP2005521695A (en) | Method of administering growth hormone by pulmonary delivery | |
CA2152684A1 (en) | Aerosol delivery of midazolam | |
EP0814790B1 (en) | Administration of ketamine for detoxification | |
Van Renterghem et al. | Intravenous versus nebulized terbutaline in patients with acute severe asthma; a double-blind randomized study | |
CZ287114B6 (en) | Therapeutic preparation in the form of aerosol and use of gas mixture | |
Crompton | Nebulized or intravenous beta 2 adrenoceptor agonist therapy in acute asthma? | |
CA2265198A1 (en) | Method of producing a nicotine medicament and a medicament made by the method | |
Verbeek et al. | Treatment of asthma-related respiratory arrest with endotracheal abuterol (Salbutamol) | |
Hasani et al. | Paediatric premedication: A comparison of sublingual buprenorphine and midazolam in children (4-10 years) scheduled for adenotonsillectomy | |
US20050154060A1 (en) | Anti-inflamatory inhalation pharmaceutical composition | |
Lahdensuo | Bronchodilator effects of fenoterol and salbutamol administered by intermittent positive pressure breathing to patients with asthma or chronic obstructive bronchitis | |
CN117899164A (en) | Novel aerosolized dosage form system and its use in the preparation of a medicament | |
Fairbanks | Cocaine: Friend or foe? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001291122 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2421974 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002528195 Country of ref document: JP |
|
REEP | Request for entry into the european phase |
Ref document number: 2001971210 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001971210 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001971210 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001291122 Country of ref document: AU |